The Company has a rich and diversified pipeline of preclinical assets balanced around its three strategic pillars: checkpoint inhibition, tumor microenvironment targeting and tumor antigen targeting but also on different antibody formats. Two of these programs were highlighted in publications and are disclosed: IPH43 (anti-MICA/B) and anti-SIGLEC-9.
Four of these projects are under the agreements signed with AstraZeneca in October 2018. The molecules under option are not disclosed. These options can be exercised before the molecules reach clinical development, triggering an option exercise fee.